Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. Eligible patients had centrally confirmed mTNBC, ≥1 systemic...
Saved in:
| Published in: | Annals of oncology Vol. 30; no. 3; p. 397 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
01.03.2019
|
| Subjects: | |
| ISSN: | 1569-8041, 1569-8041 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC.
Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival.
All enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs.
Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile.
ClinicalTrials.gov, NCT02447003. |
|---|---|
| AbstractList | Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC.
Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival.
All enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs.
Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile.
ClinicalTrials.gov, NCT02447003. Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC.BACKGROUNDTreatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC.Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival.PATIENTS AND METHODSEligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival.All enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs.RESULTSAll enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs.Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile.CONCLUSIONSPembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile.ClinicalTrials.gov, NCT02447003.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov, NCT02447003. |
| Author | Rugo, H S Awada, A Curigliano, G Iwata, H Toppmeyer, D Loi, S Loirat, D Zhao, J Adams, S Schmid, P Paluch-Shimon, S Tan, A R Cortés, J Campone, M Karantza, V O'Shaughnessy, J Winer, E P Hui, R Card, D Cescon, D W Nanda, R |
| Author_xml | – sequence: 1 givenname: S surname: Adams fullname: Adams, S email: Sylvia.Adams@nyumc.org organization: Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA. Electronic address: Sylvia.Adams@nyumc.org – sequence: 2 givenname: P surname: Schmid fullname: Schmid, P organization: Centre for Experimental Cancer Medicin, Barts Cancer Institute, Queen Mary University London, London, UK – sequence: 3 givenname: H S surname: Rugo fullname: Rugo, H S organization: Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco – sequence: 4 givenname: E P surname: Winer fullname: Winer, E P organization: Medical Oncology, Dana-Farber Cancer Institute, Boston, USA – sequence: 5 givenname: D surname: Loirat fullname: Loirat, D organization: Institut Curie, Paris, France – sequence: 6 givenname: A surname: Awada fullname: Awada, A organization: Oncology Medicine Departmen, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium – sequence: 7 givenname: D W surname: Cescon fullname: Cescon, D W organization: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada – sequence: 8 givenname: H surname: Iwata fullname: Iwata, H organization: Aichi Cancer Center Hospital, Nagoya, Japan – sequence: 9 givenname: M surname: Campone fullname: Campone, M organization: Institut de Cancerologie de l'Ouest, Nantes, France – sequence: 10 givenname: R surname: Nanda fullname: Nanda, R organization: Department of Medicin, Section of Hematology/Oncology, The University of Chicago, Chicago, USA – sequence: 11 givenname: R surname: Hui fullname: Hui, R organization: Westmead Hospital and the University of Sydney, Sydney, Australia – sequence: 12 givenname: G surname: Curigliano fullname: Curigliano, G organization: Department of Oncology and Hematology, University of Milano, Milan; IEO, European Institute of Oncology IRCCS, Milano, Milan, Italy – sequence: 13 givenname: D surname: Toppmeyer fullname: Toppmeyer, D organization: Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA – sequence: 14 givenname: J surname: O'Shaughnessy fullname: O'Shaughnessy, J organization: Baylor University Medical Center, Dallas; Texas Oncology, Dallas; US Oncology, Dallas, USA – sequence: 15 givenname: S surname: Loi fullname: Loi, S organization: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia – sequence: 16 givenname: S surname: Paluch-Shimon fullname: Paluch-Shimon, S organization: Breast Cancer Service for Young Women, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel – sequence: 17 givenname: A R surname: Tan fullname: Tan, A R organization: Levine Cancer Institute, Atrium Health, Charlotte – sequence: 18 givenname: D surname: Card fullname: Card, D organization: Merck & Co., Inc., Kenilworth, USA – sequence: 19 givenname: J surname: Zhao fullname: Zhao, J organization: Merck & Co., Inc., Kenilworth, USA – sequence: 20 givenname: V surname: Karantza fullname: Karantza, V organization: Merck & Co., Inc., Kenilworth, USA – sequence: 21 givenname: J surname: Cortés fullname: Cortés, J organization: Breast Cancer Program, Vall d'Hebron Institute of Oncology, Barcelona; Ramon y Cajal University Hospital, Madrid; IOB Institute of Oncology, Quiron Group, Barcelona, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30475950$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkL1PwzAUxC1URD9gZEUeWQIvn47ZqqpARUUZysBUOfYLDYrjYDuVws7_TSSKxHTvTj-d9G5KRo1pkJDLEG5C4PGtaIZA3mrVpyE7IZMwzXiQQxKO_t1jMnXuAwAyHvEzMo4hYSlPYUK-X1AX1tTVV6dFQbVpjN-jFW1PS2Npa_FQmc7VPfUWhUdFNXrhvPCVHKKqrTFo8H2wB6TFgDhPpWgk2jsqzd5YT-fUlHQope1eOKSrFX1avj1vtssA8ow636n-nJyWonZ4cdQZeb1fbhePwXrzsFrM14FMGPeBLFmKkCcgUh6WoFiMUOYyzlWaKwZKcilzYKyISgYxS7jkRVZkgFGcQiajaEauf3tbaz47dH6nKyexrkWDw5e7KIzzLGGQxQN6dUS7QqPatbbSwva7v-miHzjAdFM |
| CitedBy_id | crossref_primary_10_1093_annonc_mdy518 crossref_primary_10_2174_0115733947297237240530055719 crossref_primary_10_3390_cancers16112136 crossref_primary_10_1111_ajco_13385 crossref_primary_10_3390_jpm11080808 crossref_primary_10_3390_cancers11091334 crossref_primary_10_3390_cancers14092136 crossref_primary_10_3389_fonc_2022_1061789 crossref_primary_10_1186_s13578_023_01137_w crossref_primary_10_1016_j_ccell_2020_04_007 crossref_primary_10_1016_j_jgo_2019_04_014 crossref_primary_10_1016_j_medj_2025_100702 crossref_primary_10_3390_pharmaceutics13122003 crossref_primary_10_3390_cancers13194756 crossref_primary_10_1007_s00129_021_04791_8 crossref_primary_10_1177_11772719221078774 crossref_primary_10_1186_s12916_022_02527_6 crossref_primary_10_3892_ijo_2020_5060 crossref_primary_10_3390_cancers13133357 crossref_primary_10_3390_cancers13194883 crossref_primary_10_1016_j_cellsig_2025_111608 crossref_primary_10_1002_tox_24142 crossref_primary_10_1016_j_critrevonc_2020_103197 crossref_primary_10_1007_s00262_020_02736_z crossref_primary_10_1002_onco_13583 crossref_primary_10_1080_14728222_2022_2084380 crossref_primary_10_3389_fimmu_2021_765906 crossref_primary_10_1111_imr_12856 crossref_primary_10_2147_BCTT_S400055 crossref_primary_10_3390_cancers14174203 crossref_primary_10_1172_JCI140837 crossref_primary_10_2217_fon_2022_1321 crossref_primary_10_3390_ijms232314937 crossref_primary_10_1002_smll_202007051 crossref_primary_10_1007_s12282_021_01247_8 crossref_primary_10_1016_j_lanwpc_2024_101180 crossref_primary_10_1038_s41598_020_80351_9 crossref_primary_10_1038_s41523_020_00197_2 crossref_primary_10_1016_j_critrevonc_2022_103643 crossref_primary_10_2217_imt_2022_0254 crossref_primary_10_1080_2162402X_2025_2527303 crossref_primary_10_3390_cancers13246179 crossref_primary_10_1097_MD_0000000000032485 crossref_primary_10_1186_s13058_024_01785_x crossref_primary_10_1016_S0140_6736_20_32531_9 crossref_primary_10_1080_13543784_2022_2151433 crossref_primary_10_1177_1179554921996288 crossref_primary_10_1186_s13058_019_1202_4 crossref_primary_10_1007_s44178_022_00007_8 crossref_primary_10_1155_2020_9053274 crossref_primary_10_3390_genes14061160 crossref_primary_10_3390_cancers15204931 crossref_primary_10_1097_CM9_0000000000000710 crossref_primary_10_1053_j_seminoncol_2021_06_003 crossref_primary_10_1016_j_radonc_2023_109981 crossref_primary_10_1016_S1470_2045_21_00019_X crossref_primary_10_1016_j_lfs_2020_117437 crossref_primary_10_1038_s41598_021_98113_6 crossref_primary_10_1038_s41467_025_55904_z crossref_primary_10_1007_s10549_019_05371_0 crossref_primary_10_1016_j_breast_2025_104545 crossref_primary_10_3390_cancers14092102 crossref_primary_10_3389_fbioe_2021_680315 crossref_primary_10_1038_s41523_021_00346_1 crossref_primary_10_1016_j_breast_2025_104549 crossref_primary_10_1016_j_ijrobp_2020_05_011 crossref_primary_10_1186_s12943_023_01850_7 crossref_primary_10_1016_j_ebiom_2021_103684 crossref_primary_10_1016_j_pharmthera_2022_108253 crossref_primary_10_3389_fimmu_2021_669474 crossref_primary_10_1002_adma_202305215 crossref_primary_10_3390_jpm13030526 crossref_primary_10_1016_j_canlet_2025_217775 crossref_primary_10_1080_14728214_2021_1916468 crossref_primary_10_1158_1078_0432_CCR_20_3944 crossref_primary_10_1111_tbj_13713 crossref_primary_10_3390_cancers12113298 crossref_primary_10_1136_jitc_2023_007990 crossref_primary_10_3390_cancers14153811 crossref_primary_10_3389_fonc_2023_1146934 crossref_primary_10_3390_cancers16122253 crossref_primary_10_1016_j_humpath_2024_01_008 crossref_primary_10_18632_oncotarget_28747 crossref_primary_10_1038_s44321_025_00213_7 crossref_primary_10_1111_his_13946 crossref_primary_10_1016_j_critrevonc_2021_103530 crossref_primary_10_1136_jitc_2020_001008 crossref_primary_10_1016_j_ccell_2023_01_004 crossref_primary_10_3389_fimmu_2023_1060308 crossref_primary_10_1016_j_cyto_2021_155749 crossref_primary_10_1038_s41571_020_0333_y crossref_primary_10_1136_jitc_2021_003717 crossref_primary_10_1016_j_jconrel_2022_09_053 crossref_primary_10_1016_j_bbcan_2024_189193 crossref_primary_10_1515_med_2020_0138 crossref_primary_10_2217_imt_2022_0104 crossref_primary_10_1038_s41598_025_17322_5 crossref_primary_10_1080_13543784_2021_1972968 crossref_primary_10_1186_s12935_021_02299_8 crossref_primary_10_1080_14737140_2020_1823224 crossref_primary_10_3389_fonc_2022_802579 crossref_primary_10_1002_imed_70000 crossref_primary_10_1038_s41416_023_02245_7 crossref_primary_10_1007_s10549_023_06972_6 crossref_primary_10_1007_s12609_023_00492_4 crossref_primary_10_1080_21645515_2024_2335728 crossref_primary_10_1136_jitc_2022_005079 crossref_primary_10_1186_s12967_020_02454_1 crossref_primary_10_1016_j_canlet_2021_12_016 crossref_primary_10_3390_ijms22020636 crossref_primary_10_1186_s40364_021_00318_4 crossref_primary_10_3389_fimmu_2021_819405 crossref_primary_10_1007_s11912_025_01710_1 crossref_primary_10_1073_pnas_2410911121 crossref_primary_10_1016_j_intimp_2021_107876 crossref_primary_10_1016_S0140_6736_25_00553_7 crossref_primary_10_1038_s41374_022_00796_6 crossref_primary_10_1016_j_ejca_2021_02_028 crossref_primary_10_1007_s12254_019_0473_x crossref_primary_10_1186_s12885_024_13258_7 crossref_primary_10_1186_s12935_021_02242_x crossref_primary_10_3389_fonc_2022_1002667 crossref_primary_10_3390_ijms22137154 crossref_primary_10_3389_fendo_2022_810747 crossref_primary_10_1016_j_semcancer_2020_03_002 crossref_primary_10_1136_jitc_2022_005068 crossref_primary_10_3390_cancers15112933 crossref_primary_10_3390_ijms23126806 crossref_primary_10_1126_scitranslmed_aay8707 crossref_primary_10_1016_j_ejphar_2021_173867 crossref_primary_10_3390_cells10082044 crossref_primary_10_3390_biomedicines10051130 crossref_primary_10_1016_j_annonc_2020_01_072 crossref_primary_10_1016_j_drup_2025_101212 crossref_primary_10_1080_13543784_2022_2049232 crossref_primary_10_1016_j_immuni_2021_12_006 crossref_primary_10_3389_fonc_2022_877878 crossref_primary_10_1038_s41571_021_00565_2 crossref_primary_10_1177_17588359221086916 crossref_primary_10_3389_fcell_2021_727183 crossref_primary_10_1016_j_ctrv_2025_102885 crossref_primary_10_1016_j_xcrm_2025_102322 crossref_primary_10_1007_s10549_022_06547_x crossref_primary_10_1080_21645515_2025_2483022 crossref_primary_10_3389_fonc_2021_724424 crossref_primary_10_1002_cam4_6876 crossref_primary_10_1093_jnci_djab121 crossref_primary_10_3389_fonc_2021_689553 crossref_primary_10_1016_j_tranon_2020_100811 crossref_primary_10_3389_fimmu_2019_01313 crossref_primary_10_1056_NEJMe2207532 crossref_primary_10_3389_fcell_2021_730240 crossref_primary_10_1097_PGP_0000000000000782 crossref_primary_10_1016_j_clon_2025_103783 crossref_primary_10_1016_j_soin_2019_10_011 crossref_primary_10_1158_1078_0432_CCR_21_4313 crossref_primary_10_3389_fonc_2024_1423924 crossref_primary_10_1038_s41598_024_65129_7 crossref_primary_10_1016_S1470_2045_20_30754_3 crossref_primary_10_1007_s12672_025_02542_y crossref_primary_10_1053_j_seminoncol_2020_05_006 crossref_primary_10_1053_j_seminoncol_2020_05_005 crossref_primary_10_3390_cancers12092497 crossref_primary_10_1016_j_prp_2025_156226 crossref_primary_10_1002_INMD_20230025 crossref_primary_10_1136_jitc_2024_008864 crossref_primary_10_3389_fbioe_2023_1173381 crossref_primary_10_32604_or_2024_054642 crossref_primary_10_3389_fimmu_2022_947841 crossref_primary_10_1097_CM9_0000000000002631 crossref_primary_10_1097_PPO_0000000000000497 crossref_primary_10_1186_s12920_022_01348_z crossref_primary_10_3389_fonc_2022_779786 crossref_primary_10_1007_s11427_020_1714_8 crossref_primary_10_3389_fonc_2025_1635418 crossref_primary_10_3390_cancers14010109 crossref_primary_10_3389_fonc_2021_621639 crossref_primary_10_1002_2056_4538_12371 crossref_primary_10_1186_s12957_024_03424_3 crossref_primary_10_3389_fonc_2022_940171 crossref_primary_10_1002_cac2_12136 crossref_primary_10_1038_s41422_020_0375_9 crossref_primary_10_3389_fphar_2024_1345671 crossref_primary_10_1038_s41571_023_00849_9 crossref_primary_10_3389_fonc_2022_981940 crossref_primary_10_1158_1078_0432_CCR_19_1773 crossref_primary_10_1002_cac2_12183 crossref_primary_10_1186_s13058_020_01362_y crossref_primary_10_1097_CCO_0000000000000802 crossref_primary_10_1158_0008_5472_CAN_21_0253 crossref_primary_10_1007_s11864_020_00756_6 crossref_primary_10_3390_cancers14163860 crossref_primary_10_1038_s41598_022_27048_3 crossref_primary_10_3390_ijms22052608 crossref_primary_10_1007_s12282_025_01707_5 crossref_primary_10_3389_fonc_2021_562315 crossref_primary_10_3389_fmolb_2022_901392 crossref_primary_10_1002_cac2_12190 crossref_primary_10_3389_fonc_2022_1022542 crossref_primary_10_1136_jitc_2021_002597 crossref_primary_10_1007_s40487_025_00346_2 crossref_primary_10_3389_fimmu_2023_1303491 crossref_primary_10_3389_fonc_2020_598626 crossref_primary_10_3390_cancers14163996 crossref_primary_10_1016_j_canlet_2025_217822 crossref_primary_10_1007_s10549_022_06665_6 crossref_primary_10_3389_fimmu_2022_1030147 crossref_primary_10_3390_biomedicines11113037 crossref_primary_10_3389_fimmu_2025_1560257 crossref_primary_10_1016_j_cpccr_2020_100033 crossref_primary_10_1093_jjco_hyaa230 crossref_primary_10_1016_j_clim_2021_108707 crossref_primary_10_1007_s12609_019_00337_z crossref_primary_10_3389_fonc_2024_1417053 crossref_primary_10_1002_advs_202100166 crossref_primary_10_3389_fonc_2022_869078 crossref_primary_10_1177_11795549221099869 crossref_primary_10_1016_j_soc_2023_05_005 crossref_primary_10_3389_fonc_2025_1636942 crossref_primary_10_1007_s12094_024_03396_6 crossref_primary_10_1002_cam4_5757 crossref_primary_10_3390_ijms222413571 crossref_primary_10_1007_s00262_021_02919_2 crossref_primary_10_1038_s41568_024_00714_6 crossref_primary_10_1016_j_annonc_2020_02_014 crossref_primary_10_3390_life12030409 crossref_primary_10_3390_cells10020223 crossref_primary_10_1186_s40364_024_00714_6 crossref_primary_10_3389_fphar_2022_995555 crossref_primary_10_3389_fgene_2022_949852 crossref_primary_10_1007_s10549_020_05936_4 crossref_primary_10_3389_fonc_2020_582185 crossref_primary_10_3389_fonc_2020_600573 crossref_primary_10_1002_cncr_35387 crossref_primary_10_1038_s41523_025_00791_2 crossref_primary_10_1186_s12920_023_01792_5 crossref_primary_10_3390_jcm12030953 crossref_primary_10_3390_cancers13235999 crossref_primary_10_1007_s11912_021_01038_6 crossref_primary_10_1186_s13046_025_03394_8 crossref_primary_10_3892_ol_2023_13961 crossref_primary_10_1136_jitc_2021_003427 crossref_primary_10_1158_1078_0432_CCR_20_4726 crossref_primary_10_1186_s12916_019_1326_5 crossref_primary_10_1089_dna_2022_0578 crossref_primary_10_1002_advs_202205139 crossref_primary_10_1136_jitc_2023_007381 crossref_primary_10_1016_j_nantod_2022_101675 crossref_primary_10_1080_14728222_2022_2094762 crossref_primary_10_3390_cancers16010011 crossref_primary_10_1016_j_breast_2023_03_014 crossref_primary_10_1038_s41523_024_00638_2 crossref_primary_10_1016_j_yexcr_2023_113647 crossref_primary_10_3390_ijms21051594 crossref_primary_10_1097_CJI_0000000000000384 crossref_primary_10_1097_PPO_0000000000000501 crossref_primary_10_1007_s00432_021_03694_4 crossref_primary_10_1016_j_jconrel_2021_10_018 crossref_primary_10_3390_pharmaceutics15071796 crossref_primary_10_1002_adhm_202302268 crossref_primary_10_1016_j_heliyon_2024_e27103 crossref_primary_10_3389_fonc_2021_640690 crossref_primary_10_2174_0929867330666230324161329 crossref_primary_10_1016_j_prp_2020_152874 crossref_primary_10_1002_hed_70026 crossref_primary_10_1080_14712598_2020_1801627 crossref_primary_10_1016_j_semcancer_2019_10_015 crossref_primary_10_1158_1078_0432_CCR_20_1163 crossref_primary_10_1186_s12951_021_00932_2 crossref_primary_10_3390_jpm12071073 crossref_primary_10_3389_fcell_2020_00162 crossref_primary_10_3390_cancers13010080 crossref_primary_10_1007_s10549_020_05552_2 crossref_primary_10_1038_s41523_021_00287_9 crossref_primary_10_3390_cancers11071033 crossref_primary_10_1007_s10549_021_06480_5 crossref_primary_10_3390_ijms222112015 crossref_primary_10_1016_j_biopha_2024_116733 crossref_primary_10_3390_cancers14143361 crossref_primary_10_3389_fonc_2023_1209707 crossref_primary_10_3390_ijms221910476 crossref_primary_10_1038_s41591_019_0432_4 crossref_primary_10_1016_j_ijbiomac_2024_134660 crossref_primary_10_1093_annonc_mdz040 crossref_primary_10_3390_diagnostics13020272 crossref_primary_10_3389_fonc_2022_877594 crossref_primary_10_1038_s41467_020_17414_y crossref_primary_10_1186_s12929_025_01173_3 crossref_primary_10_1053_j_seminoncol_2021_09_002 crossref_primary_10_1038_s41467_022_34000_6 crossref_primary_10_1016_j_annonc_2020_11_022 crossref_primary_10_1093_jimmun_vkaf079 crossref_primary_10_1093_oncolo_oyac064 crossref_primary_10_1002_adhm_202300191 crossref_primary_10_1158_1078_0432_CCR_22_0622 crossref_primary_10_31083_j_ceog4911249 crossref_primary_10_2147_BCTT_S432526 crossref_primary_10_2217_fon_2019_0468 crossref_primary_10_1016_j_semcancer_2020_05_019 crossref_primary_10_1097_CCO_0000000000000675 crossref_primary_10_1038_s43018_021_00229_1 crossref_primary_10_1016_j_cellsig_2022_110492 crossref_primary_10_3389_fonc_2021_729175 crossref_primary_10_3389_fonc_2022_972767 crossref_primary_10_1038_s41571_018_0157_1 crossref_primary_10_1002_EXP_20240183 crossref_primary_10_1007_s11864_025_01343_3 crossref_primary_10_1158_1078_0432_CCR_24_3001 crossref_primary_10_3390_cancers14143469 crossref_primary_10_1186_s12885_022_10168_4 crossref_primary_10_1007_s12609_019_00331_5 crossref_primary_10_3389_fonc_2023_1207867 crossref_primary_10_1007_s11523_025_01157_1 crossref_primary_10_3389_fimmu_2024_1460607 crossref_primary_10_2217_imt_2020_0222 crossref_primary_10_5306_wjco_v12_i3_164 crossref_primary_10_1056_NEJMoa1910549 crossref_primary_10_1158_2159_8290_CD_20_1209 crossref_primary_10_1634_theoncologist_2019_0197 crossref_primary_10_3389_fonc_2021_756412 crossref_primary_10_1007_s12672_025_01812_z crossref_primary_10_1016_j_clbc_2024_03_004 crossref_primary_10_1186_s43556_022_00071_6 crossref_primary_10_1016_j_clbc_2024_03_001 crossref_primary_10_1111_his_15395 crossref_primary_10_1002_cac2_12465 crossref_primary_10_1038_s41523_022_00404_2 crossref_primary_10_18027_2224_5057_2020_10_3_5_14 crossref_primary_10_1002_advs_202501341 crossref_primary_10_3389_fonc_2021_686776 crossref_primary_10_1155_2019_4325105 crossref_primary_10_1007_s12609_019_00345_z crossref_primary_10_3390_ph15050574 crossref_primary_10_1038_s41571_019_0216_2 crossref_primary_10_1007_s40487_023_00224_9 crossref_primary_10_1186_s13058_020_01330_6 crossref_primary_10_3389_fendo_2022_931647 crossref_primary_10_3389_fonc_2021_650292 crossref_primary_10_3390_cancers14194885 crossref_primary_10_3389_fonc_2025_1522262 crossref_primary_10_1007_s00761_020_00729_2 crossref_primary_10_1016_j_critrevonc_2023_104103 crossref_primary_10_1038_s41523_022_00439_5 crossref_primary_10_1007_s12011_023_03632_0 crossref_primary_10_1038_s41523_021_00352_3 crossref_primary_10_1002_advs_202203699 crossref_primary_10_1186_s13045_024_01649_z crossref_primary_10_3390_biomedicines9111687 crossref_primary_10_1186_s13058_025_02082_x crossref_primary_10_2217_imt_2020_0283 crossref_primary_10_3389_fmolb_2022_903065 crossref_primary_10_1080_13543784_2020_1818067 crossref_primary_10_3390_cancers15010321 crossref_primary_10_1186_s40164_025_00667_y crossref_primary_10_3390_cancers13153697 crossref_primary_10_3390_ijms23168878 crossref_primary_10_3389_fonc_2024_1328844 crossref_primary_10_1097_MD_0000000000041739 crossref_primary_10_1186_s13058_024_01946_y crossref_primary_10_1007_s10549_020_05819_8 crossref_primary_10_3390_vaccines8020203 crossref_primary_10_1039_D3FO04807A crossref_primary_10_1111_liv_15935 crossref_primary_10_1080_13543784_2022_2159805 crossref_primary_10_1007_s10549_021_06405_2 crossref_primary_10_3390_ijms25010225 crossref_primary_10_1007_s12609_019_00346_y crossref_primary_10_3390_cancers14041042 crossref_primary_10_2147_BCTT_S482504 crossref_primary_10_1016_j_semradonc_2022_01_001 crossref_primary_10_1158_1078_0432_CCR_19_1119 crossref_primary_10_1186_s12935_025_03769_z crossref_primary_10_3389_fonc_2021_582664 crossref_primary_10_3389_fcvm_2023_1078135 crossref_primary_10_1007_s10585_024_10307_0 crossref_primary_10_1155_2021_6668573 crossref_primary_10_1016_j_hoc_2022_08_014 crossref_primary_10_1016_j_ccell_2022_11_014 crossref_primary_10_3390_cancers13164234 crossref_primary_10_2217_imt_2020_0142 crossref_primary_10_1097_CCO_0000000000000878 crossref_primary_10_1080_13543784_2022_1986002 crossref_primary_10_3389_fimmu_2024_1513421 crossref_primary_10_1007_s12094_024_03491_8 crossref_primary_10_3389_fmolb_2019_00160 crossref_primary_10_1016_j_asjsur_2023_05_174 crossref_primary_10_1007_s10238_022_00800_9 crossref_primary_10_3389_fphar_2021_653521 crossref_primary_10_3389_fonc_2021_797092 crossref_primary_10_1016_j_bbadis_2022_166515 crossref_primary_10_3390_ijms21134579 crossref_primary_10_1158_2159_8290_CD_18_1454 crossref_primary_10_1016_j_intimp_2022_109444 crossref_primary_10_1136_jitc_2019_000173 crossref_primary_10_1007_s11523_019_00689_7 crossref_primary_10_1186_s13045_023_01497_3 crossref_primary_10_1007_s12032_024_02347_z crossref_primary_10_1016_j_ijrobp_2021_08_009 crossref_primary_10_1007_s11523_020_00730_0 crossref_primary_10_33590_emjoncol_19_00193 crossref_primary_10_1016_j_semcancer_2019_12_020 crossref_primary_10_1016_j_clbc_2021_03_007 crossref_primary_10_1080_13543784_2022_2096005 crossref_primary_10_1002_cnr2_70234 crossref_primary_10_1007_s11864_023_01069_0 crossref_primary_10_3390_ph17020225 crossref_primary_10_1007_s00395_024_01090_w crossref_primary_10_1016_j_actbio_2023_05_037 crossref_primary_10_1038_s41523_025_00773_4 crossref_primary_10_3390_biomedicines10102511 crossref_primary_10_2147_CMAR_S272685 crossref_primary_10_1080_2162402X_2023_2290787 crossref_primary_10_1186_s13000_020_00971_7 crossref_primary_10_3390_ijms25021110 crossref_primary_10_1007_s40259_020_00436_9 crossref_primary_10_2147_OTT_S240655 crossref_primary_10_3390_cancers13205225 crossref_primary_10_1016_j_ctrv_2019_101947 crossref_primary_10_3389_fnut_2020_557997 crossref_primary_10_3389_fonc_2023_981239 crossref_primary_10_3390_biomedicines11061772 crossref_primary_10_1007_s12032_023_02257_6 crossref_primary_10_3390_cancers13164139 crossref_primary_10_1002_path_6423 crossref_primary_10_1177_1758835920940928 crossref_primary_10_3390_medicina60122099 crossref_primary_10_1007_s12272_019_01189_y crossref_primary_10_1038_s41417_021_00389_3 crossref_primary_10_3389_fendo_2023_1137464 crossref_primary_10_3389_fonc_2022_837963 crossref_primary_10_1038_s41416_020_01065_3 crossref_primary_10_1038_s41423_020_00565_9 crossref_primary_10_1080_21645515_2024_2385654 crossref_primary_10_1007_s00428_020_02960_z crossref_primary_10_1007_s10549_022_06780_4 crossref_primary_10_1016_j_medj_2024_01_015 crossref_primary_10_2147_CMAR_S235121 crossref_primary_10_1016_j_ctrv_2022_102352 crossref_primary_10_1136_jclinpath_2019_206252 crossref_primary_10_1038_s41523_024_00679_7 crossref_primary_10_1097_CJI_0000000000000447 crossref_primary_10_3389_fonc_2020_581733 crossref_primary_10_1007_s11912_022_01339_4 crossref_primary_10_4081_oncol_2021_497 crossref_primary_10_33590_emj_20_00039 crossref_primary_10_3390_cancers12123529 crossref_primary_10_2147_IJWH_S444202 crossref_primary_10_3390_biomedicines13092209 crossref_primary_10_4103_jcrt_jcrt_41_24 crossref_primary_10_1080_19420862_2023_2236740 crossref_primary_10_1111_1759_7714_70072 crossref_primary_10_1016_j_semcancer_2019_12_003 crossref_primary_10_1007_s40291_023_00652_3 crossref_primary_10_1016_j_bbcan_2021_188593 crossref_primary_10_1097_MD_0000000000039271 crossref_primary_10_3389_fonc_2024_1309677 crossref_primary_10_3389_fonc_2022_994276 crossref_primary_10_1007_s10555_021_09972_4 crossref_primary_10_1016_j_ctrv_2022_102462 crossref_primary_10_1007_s11864_021_00833_4 crossref_primary_10_1177_1758835920937612 crossref_primary_10_32604_or_2023_028525 crossref_primary_10_1007_s10147_019_01448_4 crossref_primary_10_1038_s41467_023_39920_5 crossref_primary_10_3892_ol_2023_14176 crossref_primary_10_3390_biomedicines9121863 crossref_primary_10_1016_j_ctrv_2024_102817 crossref_primary_10_1080_14737140_2021_1840984 crossref_primary_10_1016_j_clbc_2020_01_012 crossref_primary_10_1093_jleuko_qiae065 crossref_primary_10_1038_s41591_022_01694_6 crossref_primary_10_3390_cancers15235499 crossref_primary_10_1007_s11051_024_06000_8 crossref_primary_10_1186_s12943_023_01805_y crossref_primary_10_1007_s11684_020_0741_5 crossref_primary_10_1186_s12964_022_00854_y crossref_primary_10_1007_s12609_019_00340_4 crossref_primary_10_3390_jcm9051362 crossref_primary_10_1186_s12951_025_03311_3 crossref_primary_10_1056_NEJMoa2202809 crossref_primary_10_1155_2024_9083055 crossref_primary_10_1200_EDBK_351186 crossref_primary_10_1038_s41598_021_91995_6 crossref_primary_10_3390_app151810173 crossref_primary_10_3390_cancers16203468 crossref_primary_10_3389_fonc_2023_1199105 crossref_primary_10_1080_14740338_2021_1983541 crossref_primary_10_1158_1078_0432_CCR_21_0325 crossref_primary_10_1016_j_cpt_2023_08_002 crossref_primary_10_1038_s41392_024_02050_5 crossref_primary_10_3389_fonc_2021_681476 crossref_primary_10_1080_14656566_2020_1724283 crossref_primary_10_1016_j_biopha_2023_114695 crossref_primary_10_3390_cancers13164059 crossref_primary_10_1038_s41392_023_01672_5 crossref_primary_10_1080_14737140_2022_2139240 crossref_primary_10_1097_PAI_0000000000001062 crossref_primary_10_15252_emmm_202013412 crossref_primary_10_3390_ijms20235950 crossref_primary_10_3389_fbioe_2020_00141 crossref_primary_10_1007_s12609_021_00416_0 crossref_primary_10_1016_j_annonc_2021_07_007 crossref_primary_10_1093_carcin_bgaf006 crossref_primary_10_3389_fphar_2022_1004821 crossref_primary_10_1016_j_tranon_2023_101808 crossref_primary_10_3390_ijms26094292 crossref_primary_10_1038_s43018_023_00636_6 crossref_primary_10_1016_j_cellsig_2023_110729 crossref_primary_10_1007_s10637_025_01573_0 crossref_primary_10_1136_jitc_2023_007931 crossref_primary_10_3389_fonc_2021_815772 crossref_primary_10_3390_jcm11206021 crossref_primary_10_1002_advs_202303175 crossref_primary_10_3390_metabo12100966 crossref_primary_10_1136_jitc_2021_003091 crossref_primary_10_1186_s12885_025_13712_0 crossref_primary_10_1093_annonc_mdz115 crossref_primary_10_3389_fimmu_2021_711433 crossref_primary_10_3390_cancers14102525 crossref_primary_10_3390_cancers15030767 crossref_primary_10_1016_j_semcancer_2020_06_016 crossref_primary_10_1016_j_currproblcancer_2025_101235 crossref_primary_10_1158_2159_8290_CD_20_1647 crossref_primary_10_1177_03008916251353357 crossref_primary_10_1007_s12609_021_00418_y crossref_primary_10_1158_1078_0432_CCR_23_2947 crossref_primary_10_3390_immuno3020013 crossref_primary_10_1097_MD_0000000000037065 crossref_primary_10_1177_1758835920909091 crossref_primary_10_1080_14737140_2020_1732211 crossref_primary_10_1177_17588359221146129 crossref_primary_10_3390_ph14101008 crossref_primary_10_3390_vaccines8040562 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/annonc/mdy517 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1569-8041 |
| ExternalDocumentID | 30475950 |
| Genre | Research Support, Non-U.S. Gov't Clinical Trial, Phase II Journal Article |
| GroupedDBID | --- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 1TH 23M 2WC 4.4 482 53G 5GY 5VS 5WA 6J9 70D AAEDW AAJKP AAKUH AALRI AAMVS AAOGV AAPNW AAXUO ABEUO ABIXL ABJNI ABKDP ABLJU ABNKS ABOCM ABQLI ABZBJ ACGFO ACGFS ACPRK ACUTO ACVFH ADBBV ADCNI ADEYI ADHKW ADHZD ADOCK ADRTK ADVLN ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AEUPX AEWNT AFETI AFIYH AFJKZ AFOFC AFPUW AGCQF AGINJ AGKEF AGSYK AHMBA AHXPO AIAGR AIGII AIJHB AITUG AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN AXUDD BAWUL BAYMD BHONS BTRTY BVRKM CDBKE CGR CKLRP COF CS3 CUY CVF CZ4 DAKXR DIK DILTD D~K E3Z EBS ECM EE~ EFKBS EIF EJD FDB GJXCC GX1 H5~ HW0 HZ~ I09 IH2 J21 KAQDR KOM M-Z M41 MHKGH N9A NGC NOYVH NPM O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL RW1 TCURE TEORI TR2 W8F WOQ X7H YAYTL YFH YKOAZ ZKX ~91 7X8 |
| ID | FETCH-LOGICAL-c479t-cf75e0840a591f0d73e0f8c38d58d70dc9cc8077b2f703749c9b6b60e23506c22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 320 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000465084000012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1569-8041 |
| IngestDate | Thu Oct 02 04:37:22 EDT 2025 Mon Jul 21 05:13:06 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | pembrolizumab triple-negative breast neoplasms anti-PD-1 immunotherapy |
| Language | English |
| License | The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c479t-cf75e0840a591f0d73e0f8c38d58d70dc9cc8077b2f703749c9b6b60e23506c22 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1093/annonc/mdy517 |
| PMID | 30475950 |
| PQID | 2138647063 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2138647063 pubmed_primary_30475950 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-03-01 20190301 |
| PublicationDateYYYYMMDD | 2019-03-01 |
| PublicationDate_xml | – month: 03 year: 2019 text: 2019-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Annals of oncology |
| PublicationTitleAlternate | Ann Oncol |
| PublicationYear | 2019 |
| References | 30753266 - Ann Oncol. 2019 Mar 1;30(3):347-348. doi: 10.1093/annonc/mdz040 |
| References_xml | – reference: 30753266 - Ann Oncol. 2019 Mar 1;30(3):347-348. doi: 10.1093/annonc/mdz040 |
| SSID | ssj0006929 |
| Score | 2.7058775 |
| Snippet | Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 397 |
| SubjectTerms | Adult Aged Aged, 80 and over Anthracyclines - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects B7-H1 Antigen - genetics Bridged-Ring Compounds - administration & dosage Cohort Studies Female Gene Expression Regulation, Neoplastic - drug effects Humans Middle Aged Neoplasm Metastasis Progression-Free Survival Taxoids - administration & dosage Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology |
| Title | Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30475950 https://www.proquest.com/docview/2138647063 |
| Volume | 30 |
| WOSCitedRecordID | wos000465084000012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSxxBFC4SDcGLxphFs_CEXAurl9q8iISRSHCcg8LkNFRVV6ngLM60gfGe_533ekq8eAjk0oeGarqrXtf73lLfx9i3hBBEuFhwGYvEa5U8d7XxXDZGycJ4KUvXiU3oft8Mh3aQE26L3Fb5uCd2G3UzDZQjPyiLyqhao0c9mt1xUo2i6mqW0HjJ1iuEMtTSpYdPbOHKdiplGKJYTjw7mWMTg3gSeZlOAkb9S5m1yp5Fl52XOdn63_d7wzYzvoTjlUFssxdx8pa9PssV9B32ZxDHnpR6Hu7HzgOOykewloDwFWbU9Tu9X9wuoWtBjw2MY-vo2NFNwFuUlueTeNXRhYOnjvYWAlnO_BBIbHfewjFME-BDYXaNLhJOT-Fn71f__KLHMbCBjs_2Hbs86V18_8GzFAMPtbYtD0nLKDAYdNIWSTS6iiKZUJlGmkaLJtgQjNDal0kTo40N1iuvRCwrKVQoy_dsDSc8fmRQlsSE5ITXSdU-GKcqF52uvQ8IB53ZZfuPEzxCU6f6hZtE_PLR0xTvsg-rVRrNVpwcI6oeSivF3j-M_sQ2EPbYVSfZZ7ae8EePX9ir8Lu9Wcy_djaE1_7g7C8Z8NPi |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pembrolizumab+monotherapy+for+previously+treated+metastatic+triple-negative+breast+cancer%3A+cohort+A+of+the+phase+II+KEYNOTE-086+study&rft.jtitle=Annals+of+oncology&rft.au=Adams%2C+S&rft.au=Schmid%2C+P&rft.au=Rugo%2C+H+S&rft.au=Winer%2C+E+P&rft.date=2019-03-01&rft.eissn=1569-8041&rft.volume=30&rft.issue=3&rft.spage=397&rft_id=info:doi/10.1093%2Fannonc%2Fmdy517&rft_id=info%3Apmid%2F30475950&rft_id=info%3Apmid%2F30475950&rft.externalDocID=30475950 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1569-8041&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1569-8041&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1569-8041&client=summon |